ProKidney Corp. Class A Ordinary Shares (PROK)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

ProKidney is a clinical-stage biotechnology company. I look for businesses that already earn money and have a durable competitive edge. This one has neither yet. In fiscal Q2 2026, the quarter ended 2026-06-30, filed figures show revenue of $150,000 and a net loss of $28.4 million. For FY2025, the year ended 2025-12-31, revenue was $893,000 and net loss was $69.0 million; FY2024, the year ended 2024-12-31, had revenue of $76,000 and a net loss of $61.2 million; FY2023, the year ended 2023-12-31, had a net loss of $35.5 million. The losses are large relative to any sales. The moat, if any, would come from rilparencel, its Phase III cell therapy for advanced chronic kidney disease and type 2 diabetes, but a clinical-stage program is not a proven franchise. The balance sheet has low debt—D/E of 0.02—but trailing free cash flow is -$159.7 million, a FairStock figure, and FCF yield is -26.6% against the 2026-10-13 close. At a $599.4 million market cap, P/E is -2.85, ROE -58.96%, ROCE -35.66%, and Piotroski F-Score 0/9. The Lynch category is none because the company lost money in each of the last four years. This is a binary research bet priced well above current cash flows, not a Graham-style bargain.

In plain English: ProKidney is a clinical-stage biotech company trying to develop a cell therapy for chronic kidney disease and type 2 diabetes. It has almost no product revenue and is losing tens of millions of dollars, so the business looks weak on current financial numbers. At $1.57 per share, the price looks expensive relative to today's tiny sales and large losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer